Becton, Dickinson and Company (BDX) Stock Price, News & Analysis

Company Overview

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business. In diagnostics and life sciences, the company supplies specimen collection systems, diagnostic instrument platforms, molecular and microbiology testing systems, reagents and consumables, and laboratory automation and analytics tools that support clinical testing and biomedical research.

Founded in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson, BD has grown through organic development and strategic acquisitions to become a multinational supplier to the healthcare sector. A notable expansion of its interventional device capabilities followed the acquisition of C.R. Bard, broadening BD’s offerings in vascular, urology and oncology procedural products. The company is headquartered in New Jersey and operates globally, serving customers across North America, Europe, Asia Pacific, Latin America and other regions through a combination of direct sales and distribution partners.

BD is led by President and Chief Executive Officer Thomas E. Polen, and its organization is structured to support innovation, regulatory compliance and global supply chains that deliver products to hospitals, clinics, research laboratories and life science companies. The company emphasizes product safety, clinician and patient protection, and solutions that support clinical workflows and diagnostic decision-making.

Key Stats

• Today's Range: $143.00 to $147.44
• 50-Day Range: $144.15 to $184.16
• 52-Week Range: $127.59 to $187.35
• Volume: 3.34 million shs
• Average Volume: 2.85 million shs
• Market Capitalization: $41.04 billion
• P/E Ratio: 23.52
• Dividend Yield: 2.91%
• Price Target: $186.57
• Consensus Rating: Hold

Becton, Dickinson and Company Stock Analysis - MarketRank™

Becton, Dickinson and Company scored higher than 100% of companies evaluated by MarketBeat, and ranked 3rd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Becton, Dickinson and Company has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 7 buy ratings, 9 hold ratings, and no sell ratings.

Upside Potential

Becton, Dickinson and Company has a consensus price target of $186.57, representing about 29.4% upside from its current price of $144.15.

Amount of Analyst Coverage

Becton, Dickinson and Company has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.22%

Earnings Growth

Earnings for Becton, Dickinson and Company are expected to grow by 10.22% in the coming year, from $12.52 to $13.80 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Becton, Dickinson and Company is 23.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of Becton, Dickinson and Company is 23.52, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.04.

Price to Earnings Growth Ratio

Becton, Dickinson and Company has a PEG Ratio of 10.65. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Becton, Dickinson and Company has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.54% of the float of Becton, Dickinson and Company has been sold short.

Short Interest Ratio / Days to Cover

Becton, Dickinson and Company has a short interest ratio ("days to cover") of 2.94, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Becton, Dickinson and Company has recently decreased by 24.01%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Becton, Dickinson and Company pays a meaningful dividend of 2.81%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Becton, Dickinson and Company has been increasing its dividend for 53 years.

Dividend Coverage

The dividend payout ratio of Becton, Dickinson and Company is 68.52%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Becton, Dickinson and Company will have a dividend payout ratio of 30.43% next year. This indicates that Becton, Dickinson and Company will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.95

News Sentiment

Becton, Dickinson and Company has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Becton, Dickinson and Company this week, compared to 7 articles on an average week.

Search Interest

Only 26 people have searched for BDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

5 people have added Becton, Dickinson and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Becton, Dickinson and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $198,909.00 in company stock.

Percentage Held by Insiders

0.40% of the stock of Becton, Dickinson and Company is held by insiders.

Percentage Held by Institutions

86.97% of the stock of Becton, Dickinson and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BDX Stock Analysis - Frequently Asked Questions

How have BDX shares performed this year?

Becton, Dickinson and Company's stock was trading at $194.11 at the start of the year. Since then, BDX stock has decreased by 25.7% and is now trading at $144.1480.

How were Becton, Dickinson and Company's earnings last quarter?

Becton, Dickinson and Company (NYSE:BDX) announced its earnings results on Monday, February, 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company's revenue was up 1.6% on a year-over-year basis.
Read the conference call transcript.

How will Becton, Dickinson and Company's stock buyback program work?

Becton, Dickinson and Company's Board of Directors approved a share buyback program on Tuesday, January 27th 2026, which authorizes the company to repurchase $10,000,000 in shares, according to EventVestor. This means that the company could buy up to 0% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's board believes its shares are undervalued.

Does Becton, Dickinson and Company have any subsidiaries?

The following companies are subsidiaries of Becton, Dickinson and Company: Cytognos, Scanwell Health Inc., Tissuemed Ltd., Venclose Inc., Tepha Inc., Velano Vascular, GSL Solutions, and more.

Who are Becton, Dickinson and Company's major shareholders?

Top institutional shareholders of Becton, Dickinson and Company include Bank of New York Mellon Corp (0.59%), Fort Washington Investment Advisors Inc. OH (0.34%), Hsbc Holdings PLC (0.24%) and SG Americas Securities LLC (0.24%). Insiders that own company stock include Bertram L Scott, Claire Fraser, Michael Feld, Shana Carol Neal, Roland Goette, Michael David Garrison, Jeffrey William Henderson, Richard Byrd, Richard Byrd, David Shan, David Hickey and Thomas J Spoerel.
View institutional ownership trends.

How do I buy shares of Becton, Dickinson and Company?

Shares of BDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Becton, Dickinson and Company own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Becton, Dickinson and Company investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), ExxonMobil (XOM), Broadcom (AVGO), AbbVie (ABBV) and Chevron (CVX).

Company Calendar

• Last Earnings: 2/09/2026
• Record date for 3/31 Dividend: 3/10/2026
• Ex-Dividend for 3/31 Dividend: 3/10/2026
• Dividend Payable: 3/31/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/07/2026
• Bank of America Global Healthcare Conference 2026: 5/12/2026
• Record date for 6/30 Dividend: 6/09/2026
• Ex-Dividend for 6/30 Dividend: 6/09/2026
• Dividend Payable: 6/30/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:BDX
• CIK: 10795
• Web: www.bd.com
• Phone: (201) 847-6800
• Fax: 201-847-6475
• Employees: 72,000
• Year Founded: 1897

Price Target and Rating

• Average Price Target for Becton, Dickinson and Company: $186.57
• High Price Target: $232.00
• Low Price Target: $157.00
• Potential Upside/Downside: +29.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.44
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.13
• Trailing P/E Ratio: 23.52
• Forward P/E Ratio: 11.51
• P/E Growth: 10.43
• Net Income: $1.68 billion
• Net Margins: 8.01%
• Pretax Margin: 8.98%
• Return on Equity: 15.76%
• Return on Assets: 7.28%

Debt

• Debt-to-Equity Ratio: 0.67
• Current Ratio: 1.05
• Quick Ratio: 0.58

Sales & Book Value

• Annual Sales: $21.84 billion
• Price / Sales: 1.88
• Cash Flow: $22.74 per share
• Price / Cash Flow: 6.34
• Book Value: $88.58 per share
• Price / Book: 1.63

Miscellaneous

• Outstanding Shares: 284,740,000
• Free Float: 283,603,000
• Market Cap: $41.04 billion
• Optionable: Optionable
• Beta: 0.22